专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

31. 发明授权

US07763589B2 Compositions and methods for treating intracellular diseases 失效
标题翻译：用于治疗细胞内疾病的组合物和方法
公开(公告)号：US07763589B2
公开(公告)日：2010-07-27
申请号：US09466035
申请日：1999-12-17
申请人： Matti Sallberg , David R. Milich , William T. L. Lee
发明人： Matti Sallberg , David R. Milich , William T. L. Lee
IPC分类号： A61K48/00 , A61K39/00 , A61K39/12
CPC分类号： C07K14/005 , A61K39/12 , A61K39/29 , A61K39/292 , A61K48/00 , A61K2039/5256 , A61K2039/53 , A61K2039/545 , A61K2039/55522 , A61K2039/55566 , A61K2039/57 , C12N2710/10343 , C12N2730/10122 , C12N2730/10134 , C12N2740/13043 , C12N2770/24234 , C12N2770/24322 , Y02A50/403 , Y02A50/412 , Y02A50/478
摘要： The present invention provides methods of treating intracellular infections comprising the step of administering a vector construct which directs the expression of at least one immunogenic portion of an antigen derived from an intracellular pathogen, and also administering to the warm-blooded animal a protein which comprises the immunogenic portion of the antigen, such that an immune response is generated.
摘要翻译：本发明提供了治疗细胞内感染的方法，包括施用指导来自细胞内病原体的抗原的至少一种免疫原性部分的表达的载体构建体的步骤，以及向温血动物施用包含抗原的免疫原性部分，使得产生免疫应答。

32. 发明申请

US20100184754A1 QUINOLINONE DERIVATIVES 审中-公开
标题翻译：喹诺酮衍生物
公开(公告)号：US20100184754A1
公开(公告)日：2010-07-22
申请号：US12651612
申请日：2010-01-04
申请人： Paul A. Renhowe , Sabina Pecchi , Timothy D. Machajewski , Cynthia M. Shafer , Clarke Taylor , William R. McCrea, JR. , Christopher McBride , Elisa Jazan
发明人： Paul A. Renhowe , Sabina Pecchi , Timothy D. Machajewski , Cynthia M. Shafer , Clarke Taylor , William R. McCrea, JR. , Christopher McBride , Elisa Jazan
IPC分类号： A61K31/541 , A61K31/4709 , A61K31/497 , A61K31/5377 , A61P35/04
CPC分类号： C07D471/04 , A61K31/19 , A61K31/439 , A61K31/47 , A61K31/4709 , A61K31/4745 , A61K31/496 , A61K31/513 , A61K31/5377 , A61K31/541 , C07D401/04 , C07D401/14 , C07D405/04 , C07D409/04 , C07D413/04 , C07D417/04 , C07D453/02 , A61K2300/00
摘要： Organic compounds having the formulas I and II are provided where the variables have the values described herein. Pharmaceutical formulations include the organic compounds or pharmaceutically acceptable salts thereof and a pharmaceutically acceptable carrier and may be prepared by mixing the organic compounds or pharmaceutically acceptable salts of the organic compounds with a carrier and water. A method of treating a patient includes administering a pharmaceutical formulation according to the invention to a patient in need thereof.
摘要翻译：提供具有式I和II的有机化合物，其中变量具有本文所述的值。药物制剂包括有机化合物或其药学上可接受的盐和药学上可接受的载体，并且可以通过将有机化合物的有机化合物或药学上可接受的盐与载体和水混合来制备。治疗患者的方法包括向有需要的患者施用本发明的药物制剂。

33. 发明授权

US07754686B2 Stabilized FGF formulations containing reducing agents 有权
标题翻译：含有还原剂的稳定的FGF制剂
公开(公告)号：US07754686B2
公开(公告)日：2010-07-13
申请号：US09944930
申请日：2001-08-31
申请人： Robert V. Hageman , Bret A. Shirley , Kamaljit K. Bajwa
发明人： Robert V. Hageman , Bret A. Shirley , Kamaljit K. Bajwa
IPC分类号： A61K38/16 , A61K38/18 , C07K14/435 , C07K14/50
CPC分类号： A61K47/183 , A61K9/0019 , A61K38/1825 , A61K47/18 , A61K47/26
摘要： Stabilized FGF compositions are provided. The compositions comprise FGF or variant thereof and at least one reducing agent in an amount sufficient to inhibit FGF oxidation. Methods for increasing stability of FGF or variant thereof in a liquid or lyophilized composition and for increasing storage stability of such a composition are also provided.
摘要翻译：提供稳定的FGF组合物。组合物包含FGF或其变体和至少一种足以抑制FGF氧化的还原剂。还提供了用于提高液体或冻干组合物中FGF或其变体的稳定性和增加这种组合物的储存稳定性的方法。

34. 发明授权

US07731967B2 Compositions for inducing immune responses 有权
标题翻译：用于诱导免疫反应的组合物
公开(公告)号：US07731967B2
公开(公告)日：2010-06-08
申请号：US10837117
申请日：2004-04-29
申请人： Derek O'Hagan , Manmohan Singh
发明人： Derek O'Hagan , Manmohan Singh
IPC分类号： A61K39/00
CPC分类号： A61K39/39 , A61K2039/55511 , A61K2039/55555
摘要： The invention provides, inter alia, immunogenic compositions comprising a first antigen, at least two adjuvants, wherein a first adjuvant comprises a polymer derived from poly(lactides) and/or poly(lactide-co-glycolides), and wherein a second adjuvant comprises an imidazoquinoline, wherein said first antigen is encapsulated within, adsorbed or conjugated to, co-lyophilized or mixed with said first adjuvant, and a pharmaceutically acceptable excipient, wherein said composition elicits a cellular immune response when administered to a vertebrate subject. The invention also provides methods of producing immunogenic compositions, methods for producing a cytotoxic-T lymphocyte (CTL) response in a vertebrate subject, and methods of immunization.
摘要翻译：本发明尤其提供包含第一抗原，至少两种佐剂的免疫原性组合物，其中第一佐剂包含衍生自聚（丙交酯）和/或聚（丙交酯 - 共 - 乙交酯）的聚合物，并且其中第二佐剂包含咪唑并喹啉，其中所述第一抗原包被在所述第一佐剂中并被共冻干或混合，吸附或缀合，以及药学上可接受的赋形剂，其中所述组合物在施用于脊椎动物受试者时引起细胞免疫应答。本发明还提供产生免疫原性组合物的方法，在脊椎动物受试者中产生细胞毒性T淋巴细胞（CTL）应答的方法和免疫方法。

35. 发明授权

US07723297B2 Human FGF-21 gene and gene expression products 有权
标题翻译：人FGF-21基因和基因表达产物
公开(公告)号：US07723297B2
公开(公告)日：2010-05-25
申请号：US11405241
申请日：2006-04-17
申请人： Nobuyuki Itoh , Michael Kavanaugh
发明人： Nobuyuki Itoh , Michael Kavanaugh
IPC分类号： A61K38/18 , C07K14/475
CPC分类号： G01N33/57407 , A61K38/00 , C07K14/50 , C12P21/02 , G01N33/57426 , G01N33/57438 , G01N33/576 , G01N33/6872 , G01N33/689 , G01N2333/50 , G01N2500/00 , G01N2800/085 , G01N2800/367
摘要： This invention relates to human fibroblast growth factor (hFGF-21), and to variants thereof and to polynucleotides encoding FGF-21. The invention also relates to diagnostic and therapeutic agents related to the polynucleotides and proteins, including probes and antibodies, and to methods of treating liver disease such as cirrhosis and cancer, methods of treating conditions related to thymic function, and methods of treating conditions of the testis. The invention also relates to mouse fibroblast growth factor (mFGF-21), and to variants thereof and polynucleotides encoding mFGF-21.
摘要翻译：本发明涉及人成纤维细胞生长因子（hFGF-21）及其变体，以及编码FGF-21的多核苷酸。本发明还涉及与多核苷酸和蛋白质相关的诊断和治疗剂，包括探针和抗体，以及治疗肝脏疾病如肝硬化和癌症的方法，治疗与胸腺功能相关的病症的方法，以及治疗睾丸。本发明还涉及小鼠成纤维细胞生长因子（mFGF-21）及其变体和编码mFGF-21的多核苷酸。

36. 发明授权

US07674769B2 Treatment of severe pneumonia by administration of tissue factor pathway inhibitor (TFPI) 失效
标题翻译：通过给予组织因子途径抑制剂（TFPI）治疗重症肺炎
公开(公告)号：US07674769B2
公开(公告)日：2010-03-09
申请号：US10270478
申请日：2002-10-15
申请人： Abla Creasey
发明人： Abla Creasey
IPC分类号： A61K38/57 , C07K14/81
CPC分类号： B82Y10/00 , A61K38/57 , A61K2039/505 , A61K2300/00
摘要： Methods for prophylactically or therapeutically treating severe pneumonia involve administration of tissue factor pathway inhibitor (TFPI) or a TFPI analog to patients suffering from or at risk of developing this condition. The methods involve the use of continuous intravenous infusion of TFPI or a TFPI analog, preferably at low doses to avoid adverse side effects.
摘要翻译：用于预防或治疗重症肺炎的方法涉及组织因子途径抑制剂（TFPI）或TFPI类似物给患有或有发展该病症风险的患者。所述方法包括使用连续静脉内输注TFPI或TFPI类似物，优选低剂量以避免不良副作用。

37. 发明授权

US07671049B2 Pyrrole based inhibitors of glycogen synthase kinase 3 失效
标题翻译：基于吡咯的糖原合酶激酶抑制剂3
公开(公告)号：US07671049B2
公开(公告)日：2010-03-02
申请号：US11761937
申请日：2007-06-12
申请人： Manoj C. Desai , Simon Ng , Zhi-Jie Ni , Keith B. Pfister , Savithri Ramurthy , Sharadha Subramanian , Allan S. Wagman
发明人： Manoj C. Desai , Simon Ng , Zhi-Jie Ni , Keith B. Pfister , Savithri Ramurthy , Sharadha Subramanian , Allan S. Wagman
IPC分类号： A61K31/44 , A61K31/445 , A61K31/497
CPC分类号： C07D231/12 , C07D233/56 , C07D249/08 , C07D401/12 , C07D401/14 , C07D405/14 , C07D413/14 , C07D453/02 , C07D487/08
摘要： New pyrrole based compounds, compositions and methods of inhibiting the activity of glycogen synthase kinase (GSK3) in vitro and of treatment of GSK3 mediated disorders in vivo are provided. The methods, compounds and compositions of the invention may be employed alone, or in combination with other pharmacologically active agents in the treatment of disorders mediated by GSK3 activity, such as diabetes, Alzheimer's disease and other neurodegenerative disorders, obesity, atherosclerotic cardiovascular disease, essential hypertension, polycystic ovary syndrome, syndrome X, ischemia, traumatic brain injury, bipolar disorder, immunodeficiency or cancer.
摘要翻译：提供了新的基于吡咯的化合物，组合物和抑制糖原合酶激酶（GSK3）活性并在体内治疗GSK3介导的病症的方法。本发明的方法，化合物和组合物可以单独使用或与其它药理活性剂组合用于治疗由GSK3活性介导的病症，例如糖尿病，阿尔茨海默病和其他神经变性疾病，肥胖症，动脉粥样硬化性心血管疾病，必需的高血压，多囊卵巢综合征，X综合征，缺血，创伤性脑损伤，双相情感障碍，免疫缺陷或癌症。

38. 发明授权

US07666992B2 Pancreatic cancer genes 失效
标题翻译：胰腺癌基因
公开(公告)号：US07666992B2
公开(公告)日：2010-02-23
申请号：US11929813
申请日：2007-10-30
申请人： Giulia Kennedy
发明人： Giulia Kennedy
IPC分类号： C07K1/00 , A61K38/04 , C12P21/04 , C12P21/06 , C07H21/04
CPC分类号： C07K14/47
摘要： The present invention provides the art with the DNA coding sequences of polynucleotides that are up-or-down-regulated in cancer and dysplasia. These polynucleotides and encoded proteins or polypeptides can be used in the diagnosis or identification of cancer and dysplasia. Inhibitors of the up-regulated polynucleotides and proteins can decrease the abnormality of cancer and dysplasia. Enhancing the expression of down-regulated polynucleotides or introducing down-regulated proteins to cells can decrease the growth and/or abnormal characteristics of cancer and dysplasia.
摘要翻译：本发明提供了在癌症和发育不良中上下调的多核苷酸的DNA编码序列的技术。这些多核苷酸和编码的蛋白质或多肽可用于诊断或鉴定癌症和发育不良。上调多核苷酸和蛋白质的抑制剂可以减少癌症和发育异常的异常。增强下调多核苷酸的表达或将下调蛋白引入细胞可以降低癌症和发育不良的生长和/或异常特征。

39. 发明申请

US20100040676A1 POLYCISTRONIC HIV VECTOR CONSTRUCTS 失效
标题翻译：多氯联苯病毒构建体
公开(公告)号：US20100040676A1
公开(公告)日：2010-02-18
申请号：US12604335
申请日：2009-10-22
申请人： Jan zur Megede , Susan W. Barnett
发明人： Jan zur Megede , Susan W. Barnett
IPC分类号： A61K9/127 , C12P21/06 , A61K31/7088 , A61K38/00 , A61K9/16
CPC分类号： C07K14/005 , A61K2039/53 , C12N2740/16122 , C12N2740/16222 , C12N2740/16322 , C12N2770/36143
摘要： The present disclosure relates to vectors comprising polynucleotide sequences that encode HIV polypeptides. In particular, the disclosure relates polycistronic vector constructs comprising sequences that encode HIV polypeptides as a single polyprotein. Compositions comprising these vectors and sequences along with methods of using these vectors and sequences are also disclosed.
摘要翻译：本公开涉及包含编码HIV多肽的多核苷酸序列的载体。具体地，本公开涉及包含将HIV多肽编码为单个多蛋白的序列的多顺反子载体构建体。还公开了包含这些载体和序列的组合以及使用这些载体和序列的方法。

40. 发明授权

US07662774B2 Method for using lipoprotein associated coagulation inhibitor to treat sepsis 失效
标题翻译：使用脂蛋白相关凝血抑制剂治疗败血症的方法
公开(公告)号：US07662774B2
公开(公告)日：2010-02-16
申请号：US10891493
申请日：2004-07-15
申请人： Abla A. Creasey , George J. Broze
发明人： Abla A. Creasey , George J. Broze
IPC分类号： C07K14/00
CPC分类号： A61K38/57 , C07K14/8114 , Y02A50/473
摘要： A method for prophylactically or therapeutically treating sepsis or septic shock is described, wherein an inhibitor to tissue factor is administered to septic patients. Additionally, a method for treating inflammation is described wherein the inhibitor is administered to patients. This inhibitor is termed lipoprotein associated coagulation inhibitor, or commonly LACI. It is 38 kD and has 276 amino acids. LACI has now been shown to be useful for the treatment of sepsis, septic shock and inflammation.
摘要翻译：描述了一种用于预防或治疗性治疗败血症或败血性休克的方法，其中向败血症患者施用组织因子抑制剂。另外，描述了治疗炎症的方法，其中将抑制剂施用于患者。该抑制剂称为脂蛋白相关的凝血抑制剂，或通常为LACI。它是38 kD，有276个氨基酸。 LACI已被证明可用于治疗败血症，败血性休克和炎症。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式